|
- CNS Therapeutics | Anavex Life Sciences | New York
Anavex Life Sciences Corp (Nasdaq: AVXL) is a person-focused, biopharmaceutical company dedicated to therapeutic discovery and development of targeted CNS treatments
- Anavex Life Sciences Corp. (AVXL) Stock Price, News, Quote . . .
Anavex Life Sciences Corp , a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States
- AVXL Stock Price | Anavex Life Sciences Corp . . . - MarketWatch
Anavex Life Sciences Corp Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome
- Anavex’s Phase 2b 3 Trial of Blarcamesine (ANAVEX®2-73) in
Anavex's lead drug candidate, ANAVEX ® 2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b 3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in
- Anavex Life Sciences Reports Positive Phase IIb III Results . . .
Anavex Life Sciences Corp announced that the Journal of Prevention of Alzheimer’s Disease published results from its Phase IIb III study of blarcamesine (ANAVEX®2-73), an oral treatment
- Newsroom - Anavex Life Sciences
Get access to news, events, information and multimedia resources about Anavex Life Sciences Current and archived releases and publications are available Welcome to our newsroom
|
|
|